| Name | Title | Contact Details |
|---|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Epic Technology Consulting is a Villa Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TransparentRx is a fiduciary and transparent PBM company that specializes in providing effective solutions for self-funded employer groups, health plans, TPAs, business coalitions and government entities.
Halcyon Rehabilitation enhances the quality of life in the community we service through top tier Physical Therapy, Occupational Therapy and Speech Language Pathology focused on long term care facilities. Our population focused programs allow us to assi...
A Systematic Approach To Extractables And Leachables: A Review Of Guidance From The Industry